Aurinia Pharmaceuticals Reports Q2 Earnings: Revenue at $70M, Cash & Investments at $315.1M

Aurinia Pharmaceuticals reported Q2 EPS of 16c, beating the consensus estimate of 15c. Revenue reached $70.0M, exceeding the consensus of $63.8M. The company's cash reserves stood at $315.1M as of June 30, 2025, down from $358.5M at the end of 2024. CEO Peter Greenleaf attributed the growth to new treatment guidelines and the potential of the drug LUPKYNIS. The company plans to initiate clinical studies for its autoimmune disease drug aritinercept in the second half of this year.

Aurinia Pharmaceuticals Inc. (AUPH) reported strong financial results for the second quarter and six months ended June 30, 2025. The company's earnings per share (EPS) from continuing operations for the quarter was USD 0.16, exceeding the Zacks Consensus Estimate of USD 0.15 [2]. Revenue for the quarter reached USD 70.0 million, surpassing the Zacks Consensus Estimate of USD 63.8 million [2]. For the six months, the company's EPS was USD 0.32, compared to USD 0.07 a year ago [1].

The company's CEO, Peter Greenleaf, attributed the growth to new treatment guidelines and the potential of the drug LUPKYNIS. The company also announced that it is initiating clinical studies for its autoimmune disease drug aritinercept in the second half of this year [3]. As of June 30, 2025, the company's cash reserves stood at USD 315.1 million, down from USD 358.5 million at the end of 2024 [3].

Aurinia's shares have added about 0.8% since the beginning of the year, compared to the S&P 500's gain of 8.2% [2]. The company's stock has outperformed the market over the last four quarters, surpassing consensus EPS estimates three times [2].

The company's full-year 2025 total revenue guidance was raised to USD 260 million–USD 270 million, and net product sales guidance was increased to USD 250 million–USD 260 million [3]. The company's gross margin improved to 90% for the quarter, compared to 88% for the six months, reflecting cost controls and restructuring [3].

The company's stock is currently rated as a "Hold" by Zacks Investment Research, with a Zacks Rank #3 [2]. The company's industry, Medical - Drugs, is in the top 37% of the 250 plus Zacks industries [2].

References:

[1] https://www.marketscreener.com/news/aurinia-pharmaceuticals-inc-reports-earnings-results-for-the-second-quarter-and-six-months-ended-ju-ce7c5fdddb8bff27
[2] https://www.nasdaq.com/articles/aurinia-pharmaceuticals-auph-q2-earnings-miss-estimates
[3] https://seekingalpha.com/news/4476159-aurinia-raises-2025-revenue-outlook-to-270m-as-lupkynis-accelerates-market-penetration